VASO VASO Corp
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 839087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.2%
TTM net income YoY-5.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR-40.6%
Margins
Gross margin68.2%
Operating margin-3.7%
Net margin3.6%
FCF margin—
EBITDA margin-2.3%
Returns
ROE8.3%
ROA2.9%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio2.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.77x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.79M | $11.19M | $19.36M | $27.02M | $12.38M | $10.33M | $19.46M | $27.04M |
| Cost of revenue | $2.22M | $2.30M | $7.78M | $9.40M | $2.83M | $2.39M | $8.10M | $9.81M |
| Gross profit | $8.56M | $8.89M | $11.58M | $17.62M | $9.55M | $7.94M | $11.36M | $17.23M |
| R&D expense | $236,000 | $212,000 | $183,000 | $237,000 | $146,000 | $167,000 | $178,000 | $264,000 |
| SG&A expense | $7.70M | $7.70M | $12.72M | $28.42M | $8.02M | $7.68M | $12.40M | $14.67M |
| Operating income | $632,000 | $974,000 | -$1.33M | -$2.79M | $1.38M | $93,000 | -$1.22M | $2.15M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | $931,000 | $1.23M | -$1.07M | -$2.80M | $1.58M | $351,000 | -$1.03M | $2.32M |
| Income tax | $363,000 | $387,000 | -$188,000 | -$2.99M | $25,000 | $28,000 | $40,000 | $172,000 |
| Net income | $1.67M | $544,000 | -$887,000 | $1.13M | $1.71M | -$197,000 | -$1.07M | $2.15M |
| EBITDA | $796,000 | $1.20M | -$1.09M | -$2.46M | $1.56M | $285,000 | -$1.06M | $2.35M |
| EPS (basic) | 0.01 | 0.00 | -0.01 | — | 0.01 | 0.00 | -0.01 | — |
| EPS (diluted) | 0.01 | 0.00 | -0.01 | — | 0.01 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 176.37M | 176.34M | 175,953 | — | 175.92M | 175.74M | 175,696 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $49.95M | $38.29M | $21.97M | $34.08M | $34.86M | $32.56M | $25.31M | $26.27M |
| Receivables | — | — | — | — | $1.10M | $1.09M | $1.06M | $916,000 |
| Inventory | $812,000 | $837,000 | $827,000 | $833,000 | $893,000 | $939,000 | $965,000 | $911,000 |
| Current assets | $65.57M | $55.19M | $51.14M | $58.56M | $51.91M | $49.97M | $45.98M | $51.19M |
| PP&E, net | $89,000 | $101,000 | $1.25M | $121,000 | $1.41M | $1.85M | $1.59M | $1.54M |
| Goodwill | $1.28M | $1.26M | $10.98M | $1.23M | $15.58M | $15.57M | $15.56M | $1.18M |
| Intangibles | $1.89M | $1.72M | $2.17M | $1.25M | $1.86M | $1.82M | $1.77M | $1.61M |
| Total assets | $83.00M | $85.91M | $82.98M | $89.32M | $84.47M | $82.58M | $77.91M | $82.94M |
| Current liabilities | $29.19M | $32.86M | $30.56M | $36.85M | $31.60M | $33.02M | $30.25M | $34.72M |
| Total liabilities | $52.09M | $56.70M | $54.38M | $59.89M | $56.24M | $56.08M | $51.26M | $55.24M |
| Shareholders' equity | $30.91M | $29.21M | $28.60M | $29.43M | $28.24M | $26.50M | $26.65M | $27.70M |
| Shares outstanding | 176.24M | 176.02M | 175.95M | 175.95M | 175.95M | 175.75M | 175.70M | 175.70M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.72M | $17.44M | -$12.62M | $261,000 | $2.78M | $6.79M | -$566,000 | -$367,000 |
| Capital expenditure | $298,000 | $504,000 | $459,000 | — | -$225,000 | $504,000 | $363,000 | — |
| Free cash flow | $1.42M | $16.94M | -$13.08M | — | $3.01M | $6.29M | -$929,000 | — |
| Investing cash flow | $12.51M | -$504,000 | -$459,000 | -$83,000 | $225,000 | -$504,000 | -$363,000 | -$223,000 |
| Financing cash flow | -$169,000 | — | — | $2,000 | -$690,000 | $963,000 | -$27,000 | -$22,000 |
| Depreciation & amortization | $164,000 | $229,000 | $243,000 | $327,000 | $179,000 | $192,000 | $160,000 | $194,000 |
| Stock-based compensation | $28,000 | $11,000 | $8,000 | $8,000 | $8,000 | $9,000 | $8,000 | $28,000 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.